Lung Cancer Blood Test vs. LDCT: What Patients Should Know
Short answer
LDCT is an imaging test used for lung cancer screening in certain high-risk individuals. A lung cancer biomarker blood test provides a different type of information from a blood sample. The CIZ1B Biomarker Blood Test for Lung Cancer is designed to provide additional biomarker information that may support lung cancer assessment, but it is not intended to replace LDCT, imaging, biopsy, or a healthcare provider's clinical judgment.
If you are concerned about lung cancer risk, the most important next step is to talk with a licensed healthcare provider about screening, risk factors, and whether additional testing may be appropriate.
Why this question matters
Many people searching for lung cancer information want to know whether a blood test can replace imaging or help detect cancer earlier. That is an understandable question.
Lung cancer can sometimes develop quietly, and symptoms may not appear until later stages. Because of this, early detection and appropriate screening conversations are important, especially for people with risk factors such as smoking history, family history, certain occupational exposures, radon exposure, chronic lung disease, or other clinical concerns.
What is LDCT?
LDCT stands for low-dose computed tomography. It is an imaging test that uses a low dose of radiation to create detailed images of the lungs.
LDCT is commonly used for lung cancer screening in eligible high-risk individuals. A healthcare provider can help determine whether a person meets current screening criteria and whether LDCT is appropriate.
LDCT may help identify lung nodules or other findings that require follow-up. If something is found, a provider may recommend monitoring, additional imaging, specialist evaluation, biopsy, or other next steps depending on the clinical situation.
What is a lung cancer biomarker blood test?
A biomarker blood test looks for biological signals in the blood. These signals may provide additional information that can support a healthcare provider's assessment.
The CIZ1B Biomarker Blood Test for Lung Cancer is a minimally invasive blood test that detects a protein variant, CIZ1B, that is highly associated with lung cancer. It is currently available through licensed healthcare providers in the Dallas-Fort Worth and San Antonio metropolitan areas.
Cizzle Bio recently announced new peer-reviewed research supporting CIZ1B.
How are LDCT and a biomarker blood test different?
LDCT and biomarker blood testing provide different types of information.
| Tool | What it provides | How it may fit into assessment |
|---|---|---|
| LDCT | Imaging information about the lungs | May identify nodules or other findings that need follow-up |
| Biomarker Blood Test | Biological information from a blood sample | May provide an additional data point for clinical assessment |
These tools provide different information, and the CIZ1B Biomarker Blood Test is designed to complement LDCT, not replace it. A healthcare provider may consider imaging, biomarker information, medical history, symptoms, risk factors, and other clinical details together.
Does CIZ1B replace LDCT?
No. CIZ1B is designed to complement — not replace — LDCT, imaging, biopsy, specialist evaluation, or clinical judgment.
A CIZ1B result should be interpreted by a healthcare provider as part of a comprehensive clinical assessment. That assessment may include:
Patient history
Smoking history
Family history
Symptoms
Occupational or environmental exposures
Who should talk with a healthcare provider?
You may want to speak with a healthcare provider if you:
Have a smoking history
Have a family history of lung cancer
Have been exposed to radon, asbestos, heavy air pollution, or wildfire smoke
Have chronic lung disease
Have symptoms such as persistent cough, shortness of breath, chest discomfort, coughing up blood, unexplained weight loss, or ongoing fatigue
Are unsure whether you meet lung cancer screening criteria
Want to understand whether CIZ1B may be appropriate for your situation
Questions to ask your healthcare provider
If you are concerned about lung cancer risk, consider asking:
Am I at increased risk for lung cancer?
Should I be screened with LDCT?
Could biomarker testing provide additional information?
How would CIZ1B results be interpreted with my medical history and imaging?
Is CIZ1B available through your practice?
What should I do if I have symptoms or risk factors?
For healthcare providers
Licensed healthcare providers may consider the CIZ1B Biomarker Blood Test for Lung Cancer as an additional biomarker tool during lung cancer assessment.
Providers in Dallas-Fort Worth and San Antonio can review clinical resources and ordering setup steps.
For patients
CIZ1B is available through licensed healthcare providers in Dallas-Fort Worth and San Antonio. Patients interested in the test should speak with their healthcare provider about whether it may be appropriate.
Learn about CIZ1B and bring questions to your healthcare provider.
FAQ
Can a blood test replace LDCT for lung cancer screening?
No. A lung cancer biomarker blood test should not be assumed to replace LDCT. LDCT and biomarker blood testing provide different types of information. A healthcare provider can explain how screening, imaging, and additional testing may apply to your situation.
Can lung cancer be detected through a blood test?
Some biomarker blood tests are designed to provide information that may support cancer assessment. CIZ1B is designed to provide additional biomarker information that may support lung cancer assessment, but results should be interpreted by a healthcare provider alongside other clinical information.
Who can order the CIZ1B Biomarker Blood Test for Lung Cancer?
The CIZ1B test is ordered through licensed healthcare providers.
Where is the CIZ1B test available?
The CIZ1B test is currently available through licensed healthcare providers in the Dallas-Fort Worth and San Antonio metropolitan areas.
What should I do if I am worried about lung cancer?
Talk with a healthcare provider. They can review your risk factors, symptoms, screening eligibility, and whether additional testing may be appropriate.
